CHICAGO TRUST Co NA Invests $294,000 in Insulet Co. (NASDAQ:PODD)

CHICAGO TRUST Co NA acquired a new position in Insulet Co. (NASDAQ:PODD) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 1,125 shares of the medical instruments supplier’s stock, valued at approximately $294,000.

Several other large investors have also recently bought and sold shares of the business. QRG Capital Management Inc. acquired a new stake in shares of Insulet during the third quarter worth approximately $297,000. Fisher Asset Management LLC boosted its stake in shares of Insulet by 0.9% during the 3rd quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier’s stock valued at $81,719,000 after buying an additional 3,113 shares during the period. Orion Portfolio Solutions LLC grew its holdings in shares of Insulet by 86.2% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 7,826 shares of the medical instruments supplier’s stock valued at $1,822,000 after acquiring an additional 3,623 shares in the last quarter. Nomura Asset Management Co. Ltd. increased its stake in shares of Insulet by 5.7% in the third quarter. Nomura Asset Management Co. Ltd. now owns 153,416 shares of the medical instruments supplier’s stock worth $35,708,000 after acquiring an additional 8,301 shares during the last quarter. Finally, Stifel Financial Corp raised its holdings in shares of Insulet by 2.8% during the third quarter. Stifel Financial Corp now owns 10,527 shares of the medical instruments supplier’s stock worth $2,450,000 after acquiring an additional 290 shares in the last quarter.

Insider Activity at Insulet

In other news, CAO Lauren Budden sold 915 shares of the stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the transaction, the chief accounting officer now owns 5,733 shares in the company, valued at approximately $1,580,129.46. This represents a 13.76 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.47% of the stock is currently owned by corporate insiders.

Insulet Price Performance

Shares of PODD stock opened at $267.99 on Tuesday. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $279.77. The company has a market capitalization of $18.80 billion, a P/E ratio of 45.89, a P/E/G ratio of 4.12 and a beta of 1.22. The stock has a 50 day moving average of $264.57 and a two-hundred day moving average of $230.93. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Wall Street Analysts Forecast Growth

PODD has been the subject of several research reports. Morgan Stanley lifted their price target on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a report on Monday, November 11th. Sanford C. Bernstein assumed coverage on shares of Insulet in a research note on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 target price for the company. Canaccord Genuity Group raised their price target on shares of Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a report on Monday, December 9th. Barclays lifted their price objective on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Finally, Raymond James increased their target price on shares of Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research report on Monday, October 14th. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $272.81.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.